Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AGS-v Vaccine
NCT03055000Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AGS-v PLUS in mosquito-borne diseases (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Subjects With 1 or More Adverse Events at 1 year, Cytokine Levels (GM-CSF, IL-10, IL-1B, IL-2, IL-4, IL-5, IFN-gamma, TNF-a) and 1 more. Started Feb 2017; status: completed.
02
Drugs
AGS-v PLUS
03
Conditions
mosquito-borne diseases
Beyond the preview
Go deeper on NCT03055000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055000.